Fundraising Fox
Clementia
6,695 employees on LinkedIn · 2 known investors
Find your way into Clementia
Sign up to see every warm intro you have to Clementia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clementia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
Investors · 2
Acquisitions · 2
Early investors' stakes continue via these dealsImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.
Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases. The company is a late-stage biotech enterprise collaborating with academic institutions and pharmaceutical partners to advance its pipeline.
In the news
Frequently asked questions
- What does Clementia do?
- Ipsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
- Who are Clementia's investors?
- Clementia's investors include New Enterprise Associates (NEA), Ysios Capital.